The Crasta Lab aims to integrate personalised medicine into clinical practice from a chromosomal instability perspective. The lab's research aims to identify novel cellular targets that could be of relevance to the development of combination therapies to improve sensitization of tumour cells, as well as provide insights into chemoresistance, a major setback in oncology. The lab has recently identified a novel route to chemoresistance upon antimitotic chemotherapy (most-commonly used front-line therapy in a wide spectrum of cancers). Current studies are now focused on elucidating the influence on immune function (both innate and adaptive), understanding the impact of the tumour microenvironment in dictating cell death versus survival during chemotherapy, as well as profiling global genomic, transcriptomic, proteomic and lipidomic changes. Results obtained will aid illuminate the role of abnormal mitosis/aneuploidy and associated altered cell signaling, metabolic and immune changes in cancer progression and therapy.